Tocilizumab in Acute Coronary Syndromes: A Systematic Review of Randomized Controlled Trials
This systematic review synthesizes the randomized controlled trial (RCT) evidence for tocilizumab, an interleukin-6 (IL-6) receptor antagonist, as an adjunctive therapy in acute coronary syndrome (ACS). IL-6 is a central mediator of the inflammatory response that follows myocardial infarction and contributes to ischemi...